Welcome to our dedicated page for STANDARD BIOTOOLS SEC filings (Ticker: LAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Standard BioTools Inc. (NASDAQ: LAB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including Forms 10-K, 10-Q and 8-K. These documents offer detailed information about its analytical laboratory instrument manufacturing business, which focuses on SomaScan, mass cytometry and microfluidics technologies used in proteomics and genomics research.
Current reports on Form 8-K are particularly important for tracking material events at Standard BioTools. Recent 8-K filings describe quarterly financial results, including revenue from continuing operations and segment performance, as well as operational restructuring plans involving reductions in force and the consolidation of South San Francisco-based R&D into the company’s Singapore facility. Other 8-Ks detail governance and compensation matters, such as changes to equity incentive plans and retention awards for senior executives.
A key filing for LAB is the Form 8-K describing the Stock Purchase Agreement with Illumina, Inc., under which Illumina will acquire SomaLogic, Inc. and related entities that operate Standard BioTools’ aptamer-based and functional proteomics business. This filing outlines the transaction structure, cash consideration, potential earnouts and royalty arrangements, and the fact that the company’s mass cytometry and microfluidics businesses are being retained.
On Stock Titan, these SEC filings are updated from EDGAR and paired with AI-powered summaries that highlight the main points, such as changes in revenue outlook, restructuring costs, or the terms of significant transactions. Users can quickly identify items related to results of operations, exit or disposal activities, and material definitive agreements, and then drill into the full text of each filing for deeper analysis of LAB’s financial condition, strategic direction and corporate governance.
Standard BioTools Inc. furnished an 8-K announcing it issued a press release with selected financial results for the three and nine months ended September 30, 2025. The release is attached as Exhibit 99.1.
Sections titled “Operational Restructuring” and “Full Year 2025 Revenue Outlook,” along with the forward-looking statement disclaimer, are furnished under Regulation FD. The information in Items 2.02 and 7.01, including Exhibit 99.1, is expressly furnished and not deemed filed under the Exchange Act.
Standard BioTools Inc. has begun a restructuring plan that includes reducing its global workforce by approximately 15%. The company explains that this move is intended to improve operational efficiency and lower operating costs so they better match its current revenue projections, while still supporting its long-term strategic plan.
The company expects to record about $7.5 million in expenses related to this reduction-in-force, mainly for cash severance, termination benefits, and related costs. These costs are expected to be paid over the next several months, and the company notes that actual expenses could differ and that additional costs may arise in connection with the broader operational restructuring.
Casdin-related entities and Eli Casdin reported a purchase of 100,000 shares of Standard BioTools, Inc. common stock at a weighted-average price of $1.2892 per share on 09/09/2025. The filing shows the shares were acquired in multiple transactions within a narrow price range and that the reporting persons hold large indirect positions: the Master Fund is shown as directly owning securities and several affiliated funds and entities are listed as indirect owners, with a reported total of 60,875,000 shares beneficially owned by the Master Fund reporting group after the transaction. The report also discloses direct ownership by Eli Casdin and by two Casdin private growth funds, and notes deputization of Mr. Casdin to represent the reporting persons on the company board.
Casdin-affiliated investment entities reported new open-market purchases of Standard BioTools Inc. common stock. Casdin Partners Master Fund, L.P., which is treated as a director and 10% owner, bought 250,000 shares on September 3, 2025 at a weighted average price of $1.2656 and another 250,000 shares on September 4, 2025 at a weighted average price of $1.2774.
After these transactions, the Master Fund indirectly beneficially owned 60,775,000 shares of Standard BioTools common stock. Footnotes state these securities are held directly by the Master Fund and may be deemed indirectly beneficially owned by Casdin Capital, LLC, Casdin Partners GP, LLC, and Eli Casdin. Separate positions are also reported as held directly by Eli Casdin and by other Casdin private growth equity funds.
Standard BioTools Inc. plans to consolidate its South San Francisco R&D operations into its Singapore facility and implement a reduction-in-force affecting certain U.S. R&D employees, including members of management. The move is part of a broader effort to restructure operating expenses, improve operational efficiency and reduce operating costs while supporting the company’s long-term strategic plan.
The company currently expects expenses related to the reduction-in-force to be approximately $3.6 million, primarily for cash severance, termination benefits and related costs, including about $0.9 million of non-cash expenses from vesting of share-based awards. These costs are expected to be payable over the next several months, and the company notes that actual costs may differ and that the restructuring could adversely affect sales and development activities.
Standard BioTools director and 10% owner entities associated with Eli Casdin reported a series of open‑market purchases of common stock. Casdin Partners Master Fund, L.P. bought 200,000 shares on August 22, 2025 at $1.2634, 200,000 shares on August 25 at a weighted average $1.2409, and 125,000 shares on August 26 at $1.2635.
After these trades, the Master Fund held 60,275,000 shares indirectly for the reporting group. Separate positions include 2,901,062 shares held directly by Eli Casdin, 13,939,637 shares held by Casdin Private Growth Equity Fund II, L.P., and 2,744,219 shares held by Casdin Private Growth Equity Fund, L.P.
Michael Egholm, President & CEO and Director of Standard BioTools Inc. (LAB), reported a transaction dated 08/20/2025 in which 54,919 shares of common stock were disposed (Transaction Code F) at $1.27 per share. The filing states these shares were withheld to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on May 20, 2024 and March 21, 2025, previously reported on Form 4s. After the withholding, the reporting person beneficially owns 5,681,366 shares, held directly. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Egholm.
Sean Mackay, SVP & Chief Business Officer of Standard BioTools Inc. (LAB), reported a disposition of 19,661 shares of common stock on 08/20/2025. The filing shows the sale was coded F and executed at $1.27 per share. The report explains these shares were withheld to satisfy tax withholding obligations arising from the vesting of restricted stock units originally granted on May 20, 2024 and March 21, 2025.
After the withholding, Mackay beneficially owns 799,496 shares, held directly. The transaction is a routine withholding to cover taxes tied to equity compensation rather than an open-market sale for other purposes.
Standard BioTools (LAB) Chief Financial Officer Hanjoon Alex Kim reported a disposition of 12,739 shares of common stock on 08/20/2025 at a price of $1.27 per share. The Form 4 shows the shares were withheld to satisfy tax withholding obligations arising from restricted stock units that vested from grants made on May 20, 2024 and March 21, 2025. After the reported disposition, the reporting person beneficially owns 2,427,825 shares. The filing was signed by an attorney-in-fact on behalf of Mr. Kim on 08/22/2025.
Casdin-affiliated entities reported multiple open-market purchases of Standard BioTools Inc. (LAB) common stock between 08/13/2025 and 08/15/2025. The filings show aggregated acquisitions of at least 358,220 shares at weighted-average prices of approximately $1.21–$1.31, resulting in total beneficial ownership of 59,750,000 shares (held indirectly by the reporting entities) and certain direct holdings by Eli Casdin. The report also discloses a 2,901,062-share disposition directly by Eli Casdin and additional direct holdings of 13,939,637 and 2,744,219 shares by two Casdin funds. Eli Casdin is deputized to represent the reporting persons on LAB's board.